Very truly yours,

Steven C. Sunshine,

Counsel for Waste Management, Inc.

Neal R. Stoll,

Counsel for Eastern Environmental Services, Inc.

Agreed and Acknowledged:

Anthony E. Harris,

U.S. Department of Justice.

cc: Douglas L. Kilby, Esq., State of Florida
James A. Donahue, III, Esq., Commonwealth of Pennsylvania
Richard F. Grimm, Esq., State of New York

Certificate of Service

I certify that on February 1, 1999, I caused a copy of the foregoing Competitive Impact Statement to be served on the parties in this case by mailing the pleading first-class, postage prepaid, to a duly authorized legal representative of each of the parties as follows:

Jonathan L. Greenblatt, Esquire

Steven C. Sunshine, Esquire

Michael Strub, Jr., Esquire,

Shearman & Sterling, 801 Pennsylvania Avenue, NW, Washington, DC 20004–2604.

James R. Weiss, Esquire,

Preston Gates Ellis & Rouvelas Meeds LLP, 1735 New York Avenue, NW, Washington, DC 20006–8425.

Counsel for Defendants Waste Management, Inc. and Ocho Acquisition Corp.

Neal R. Stoll, Esquire,

Skadden, Arps, Slate, Meagher & Flom, 919 Third Avenue, New York, NY 10022–3897.

Counsel for Defendant Eastern Environmental Services, Inc.

Richard E. Grimm

Kay Taylor,

Assistant Attorneys General, Antitrust Bureau, Office of the Attorney General, State of New York, 120 Broadway, Suite 26–01, New York, NY 10271.

Counsel for Plaintiff State of New York

James A. Donahue, III,

Chief Deputy Attorney General

Benjamin L. Cox,

Deputy Attorney General, 14th Floor, Strawberry Square, Harrisburg, PA 17120.

Counsel for Plaintiff Commonwealth of Pennsylvania

Lizabeth A. Leeds

Douglas L. Kilby,

Assistant Attorneys General, Antitrust Section, PL–01, The Capitol, Tallahassee, FL 32399–1050.

Counsel for Plaintiff State of Florida

Anthony E. Harris, Esq.,

U.S. Department of Justice, Antitrust Division, 1401 H Street, NW, Suite 3000, Washington, DC 20530, (202) 307–6583.

[FR Doc. 99–3925 Filed 2–25–99; 8:45 am]

BILLING CODE 4410–11–M

DEPARMTENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances; Notice of Application

Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a regulation under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with Section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on December 21, 1998, Lonza Riverside, 900 River Road, Conshohocken, Pennsylvania 19428, made application by renewal to the Drug Enforcement Administration to be registered as an importer of phenylacetone (8501), a basic class of controlled substance listed in Schedule II.

The firm is importing the phenylacetone to manufacture dextroamphetamine sulfate.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of this basic class of controlled substance may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than March 19, 1999.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745–46 (September 23, 1975), all applicants for registration to import a basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: February 5, 1999.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 99–4753 Filed 2–25–99; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 23, 1998, Medeva Pharmaceuticals CA, Inc., 3501 West Garry Avenue, Santa Ana, California 92704, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Methylphenidate (1724)	II
Diphenoxylate (9170)	II

The firm plans to manufacture the listed controlled substances to make finished dosage forms for distributions to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 27, 1999.

Dated: February 5, 1999.

John H. King,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 99–4754 Filed 2–25–99; 8:45 am]

BILLING CODE 4410–09–M